Strategic partnerships Cygnus has a track record of collaborating with biotech players and contract manufacturers, evidenced by recent partnerships and joint developments such as the Dyadic collaboration for C1 HCP ELISA and broader Constellation Solutions initiatives. This suggests sales opportunities through co-developed assays, licensing arrangements, and expanded service offerings with partner networks.

Broad impurity analytics The company specializes in host cell proteins and process-related impurities with innovative approaches like MockV virus clearance kits and Antibody Affinity Extraction technology. This positions Cygnus to cross-sell comprehensive analytics suites to biopharma firms seeking end-to-end impurity testing across development stages and product types.

Regulatory pedigree Cygnus’ assays have supported multiple licensed biologics and 28 FDA- and EMA-approved cell and gene therapies, underscoring strong regulatory credibility. This can be leveraged to target sponsors aiming for faster regulatory timelines and confidence in lot release testing and validation services.

Expansion readiness With ongoing product launches such as C1 HCP ELISA and MockV RVLP kits, plus a history of innovative assay development, Cygnus is positioned to scale services to growing biopharma pipelines, offering modular and rapid deployment of new analytical tools to meet expanding demand.

Technology-led value The integration of Mass Spectrometry, AAE, ELISA, and non-infectious mock virus approaches highlights a tech-forward value proposition. This enables upsell to clients seeking cutting-edge analytics, faster characterization of impurities, and robust viral clearance studies as they migrate to complex biologics and gene therapies.